Highnoon Laboratories Limited (PSX: HINOON) has successfully reaffirmed its strong credit ratings, reflecting the company’s solid market position and robust financial management. VIS Credit Rating Company Limited (VIS) maintained Highnoon’s entity ratings at A+ for long-term and A1 for short-term with a Positive outlook, signaling good credit quality and strong liquidity.
Read More: Mercantile and Transworld Home Partner to Bring Exclusive Offer on Latest Apple MacBook Neo
The reaffirmed rating emphasizes Highnoon’s resilience within a medium-to-low risk pharmaceutical sector, supported by consistent domestic demand and regulatory pricing stability. Despite ongoing industry-wide pressures and regional export disruptions, the company has maintained steady revenue growth through a well-diversified product portfolio and prudent pricing strategies.
Key Rating Strengths
| Rating Factor | Assessment |
|---|---|
| Long-Term Rating | A+ (Good credit quality) |
| Short-Term Rating | A1 (Strong liquidity) |
| Outlook | Positive |
| Sector Risk | Medium-to-low (pharmaceuticals) |
Revenue Diversification and Risk Management
Notably, the company’s top five products contribute around 26% of total sales, reflecting low revenue concentration risk. This diversification reduces the company’s vulnerability to performance fluctuations in any single product category.
Capital Structure and Deleveraging
Highnoon’s conservative capital structure and strong internal capital generation have enabled active deleveraging and reduced dependence on external borrowings, resulting in favorable gearing metrics. The company’s liquidity reserves and projected operational cash flows are expected to comfortably support planned investments in manufacturing expansion, further reinforcing its financial stability.
Future Outlook
Looking ahead, the ratings remain underpinned by Highnoon’s ability to manage the financial implications of new debt mobilization for planned facilities, positioning the company for sustainable growth and enhanced market capacity.
About Highnoon Laboratories Limited
Established in 1984, Highnoon Laboratories is a leading pharmaceutical company in Pakistan, engaged in the manufacturing, importing, and marketing of a wide range of therapeutic products. The company’s registered office and manufacturing facilities are located on Multan Road, Lahore. Highnoon produces treatments for respiratory, inhalation, cardiology, and diabetes-related conditions, ranking as the 13th largest pharmaceutical company in the country with a market share of 2.55%.
Through its wholly owned subsidiary, Curexa Health Private Limited, Highnoon also produces antibiotics, particularly cephalosporins. Curexa’s cGMP-compliant facilities manufacture sterile powders for injections, oral suspension powders, and capsules for both local and international markets, covering therapeutic areas such as respiratory, gastroenterology, urology, gynecology, and pediatrics.
About VIS Credit Rating Company Limited
VIS Credit Rating Company Limited (VIS) is one of Pakistan’s leading credit rating agencies, providing independent assessments of creditworthiness for corporations, financial institutions, and government entities. VIS ratings are widely recognized by investors, regulators, and market participants.
